Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/184321
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Blanco Fernández, Bárbara | - |
dc.contributor.author | Garrido, Cristina | - |
dc.contributor.author | Rubí Sans, Gerard | - |
dc.contributor.author | Sánchez Cid, Lourdes | - |
dc.contributor.author | Guerra Rebollo, Marta | - |
dc.contributor.author | Rubio Vidal, Núria | - |
dc.contributor.author | Mateos Timoneda, Miguel Ángel | - |
dc.contributor.author | Engel, Elisabeth | - |
dc.contributor.author | Pérez Amodio, Soledad | - |
dc.date.accessioned | 2022-03-22T12:01:14Z | - |
dc.date.available | 2023-01-13T06:10:24Z | - |
dc.date.issued | 2021-02-01 | - |
dc.identifier.issn | 0928-4931 | - |
dc.identifier.uri | http://hdl.handle.net/2445/184321 | - |
dc.description.abstract | Thymidine kinase expressing human adipose mesenchymal stem cells (TK-hAMSCs) in combination with ganciclovir (GCV) are an effective platform for antitumor bystander therapy in mice models. However, this strategy requires multiple TK-hAMSCs administrations and a substantial number of cells. Therefore, for clinical translation, it is necessary to find a biocompatible scaffold providing TK-hAMSCs retention in the implantation site against their rapid wash-out. We have developed a microtissue (MT) composed by TKhAMSCs and a scaffold made of polylactic acid microparticles and cell-derived extracellular matrix deposited by hAMSCs. The efficacy of these MTs as vehicles for TK-hAMSCs/GCV bystander therapy was evaluated in a rodent model of human prostate cancer. Subcutaneously implanted MTs were integrated in the surrounding tissue, allowing neovascularization and maintenance of TK-hAMSCs viability. Furthermore, MTs implanted beside tumors allowed TK-hAMSCs migration towards tumor cells and, after GCV administration, inhibited tumor growth. These results indicate that TK-hAMSCs-MTs are promising cell reservoirs for clinical use of therapeutic MSCs in bystander therapies. | ca |
dc.format.extent | 13 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Reproducció del postprint publicat a: https://doi.org/10.1016/j.msec.2020.111854 | - |
dc.relation.ispartof | Materials Science & Engineering C-Materials For Biological Applications, 2021, vol 121 | - |
dc.relation.uri | https://doi.org/10.1016/j.msec.2020.111854 | - |
dc.rights | cc by-nc-nd (c) Elsevier, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) | - |
dc.subject.classification | Nanomedicina | - |
dc.subject.classification | Càncer | - |
dc.subject.other | Nanomedicine | - |
dc.subject.other | Cancer | - |
dc.title | Engineered microtissues for the bystander therapy against cancer | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.date.updated | 2022-03-11T09:44:39Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/712754/EU//BEST | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 6470487 | - |
dc.identifier.pmid | 33579487 | - |
Appears in Collections: | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) Publicacions de projectes de recerca finançats per la UE |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
2021_MatSciEngC_EngineeredMicro_Engel_Postprint.pdf | 1.58 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License